InCarda Therapeutics

Headquarters:
Palo Alto, CA

Deal Team:
Lou Lange

InCarda Therapeutics, Inc. is a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. The advantage of inhalation is that it delivers “first pass” to cardiac tissue, presenting a bolus of a drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and more importantly can be patient administered.

AMV

AMV is a venture capital firm investing in
early-stage digital health, technology and
life sciences companies.

 

2100 Geng Road, Suite 200
Palo Alto, CA
650.621.8808

© 2017 Asset Management Ventures
All Rights Reserved